Introduction
U ncontrolled bleeding remains the leading cause of preventable death in the battlefield 1 and effective control of hemorrhage can improve outcome. 2, 3 Historically, approximately 20% of the combat casualties are killed in action (KIA), defined as being killed before reaching a treatment facility. 4 The major causes of death in this group are hemorrhage (50%) and neurological trauma (36%), whereas the rest are from devastating multiple injuries. Even when the injured survive long enough to be transported to a medical facility, hemorrhage still remains the leading cause of late death and complications (died of wounds [DOW] ). The percentage of soldiers that are KIA has remained unchanged since the American Civil War (approximately 20%); however, the percentage of DOW has declined markedly over time. [5] [6] [7] The DOW rates decreased from 8 to 2.5% between World War I and the Korean War. It should be noted that in recent conflicts that were fought in urban settings (Northern Ireland, Somalia) the DOW numbers increased more than two-fold compared with more conventional wars such as Korea and Vietnam. 8 Although debatable, different mechanism of injuries (bullets vs. fragments) and delayed evacuation to definitive care are two of the most likely reasons. In the ongoing war in Iraq, the total number of casualties is low, 9 but the data from the early phase of the conflict showed an unchanged KIA rate. According to the information released by the Pentagon, by early September 2003 the total number of U.S. casualties in Iraq was 1,406 with 1,124 wounded (79.95%) and 282 dead (20.05%). 10 In the KIA group, the bleeding source can either be inside a body cavity such as chest or abdomen (and thus not easily accessible) or external (suitable for application of dressings and/or tourniquets). Theoretically the external sources can be controlled by compression but the reality is quite different. In a review of Vietnam War data, almost 40% of soldiers that were KIA because of exsanguination had a source of hemorrhage that could have been controlled in the field. 11 Early and effective hemorrhage control is obviously important and can theoretically save more lives than any other measure; however, the best strategy to achieve this goal in austere and hostile combat situations is not clear. The ideal method for hemorrhage control should be suitable for application by a layperson with effective control of bleeding from a variety of sources within minutes, and it should be associated with a low complication rate. An area of increasing concern is lethal hemorrhage from sites that are not suitable for application of tourniquets or compression dressings (e.g., complex groin wounds), as seen during the conflicts in Somalia and Afghanistan.
The recent military conflicts have renewed an interest in the development of better hemostatic agents for the battlefield. When subjected to rigorous testing, a number of these new agents were found to be no better than regular dressings; however, a few were very effective, and some have recently been approved by the Food and Drug Administration (FDA). Of the newly developed products, four seemed especially promising and three of these have been deployed for use in the most current conflict, "Operation Iraqi Freedom" (Table I) .
Under ordinary circumstances, new drugs and devices are tested by multiple researchers through randomized clinical trials before widespread utilization. Emergencies such as a large military conflict, however, create a unique challenge. The decision to use (or not to use) the product cannot wait for the "ideal" data (large randomized clinical trial) and may have to be made based upon the "best available" data. The hemostatic agents deployed to the U.S. troops have been extensively tested in animal models of severe hemorrhage, but most of this information is still unpublished, and no randomized clinical trials involving trauma patients have been conducted to test these products. The decision to deploy these agents therefore requires an analysis of the best available information with special emphasis on the unique requirements of the troops.
Recently, a panel of subject matter experts reviewed all the available data regarding one hemostatic agent (mineral zeolite) and endorsed its use by the U.S. Marine Corps. On the other hand, the U.S. Army has chosen a different hemostatic agent as their mainstay. This report provides a brief description of these agents and reviews the data supporting the use of these new hemostatic dressings by the U.S. military. A summary of the recommendation by the expert panel and the rationale are also presented.
Poly-N-acetyl Glucosamine-Based Hemostatic Dressings
Poly-N-acetyl glucosamine (P-NAG) is a naturally occurring, biodegradable, complex polysaccharide. It is found in a variety of marine life and is commercially obtained by fermentation process and isolated from microalgal cultures. Generally, P-NAG is called chitin when it is predominantly acetylated, and chitosan when most of the compound is deacetylated. Mechanisms of action are not entirely clear but may include adhesiveness to tissues, attraction of circulating blood cells, nitric oxide scavenging with vasospasm, etc. Both of these formulations of P-NAG have been used (in the form of thin sheets or liquid) to control bleeding from a variety of minor injuries, such as peritoneal abrasions, 12 surface splenic lacerations, splenic capsular tears, 13 intestinal wall incisions (humans), 14 capillary oozing in brain, 15 and lingual injury. 16 However in only one animal study, efficacy of chitosan has been demonstrated in a large animal model of uncontrolled brisk hemorrhage (liver injury). 17 In this study, there was a significant difference in the volume of blood loss (246 mL versus 2,879 mL), fluid used for resuscitation (1.8 L versus 6.6 L), and survival (87.5% versus 28.6%) in the chitosan group compared with gauze control. The chitosan dressing used in this study was manufactured by HemCon, Inc. (Lake Oswego, Oregon) and supplied as 10.2 ϫ 10.2 ϫ 0.4-cm sponges with medical foam backing. More information about this product is available on the manufacturer's web site (www.hemcon.com).
This dressing received approval from the FDA in November 2002 as a device (through a 510(k) submission), and Department of Defense (particularly U.S. Army) and other government agencies have placed an order for 30,000 dressings. Approximately 3,000 HemCon dressings have already been shipped to the U.S. Army units in Iraq, and it has been used in 40 cases so far. This agent does not have any known side effects and costs about $100 per dressing. It is stable and has no special storage requirements. One limiting factor is the current rate of manufacturing (approximately 600 per week), which is expected to increase (1,200 per week) in the near future.
It should be noted that all forms of chitin or chitosan bandages are not equally effective. Also the effectiveness may vary from batch to batch. For example, an FDA-approved chitin dressing (rapid deployment hemostat [RDH]); Marine Polymer Technologies, Danvers, Massachusetts) was tested by two leading trauma research teams in almost identical animal models of liver injury and was found to be either extremely effective 18 or completely ineffective. 19 This obviously raises concerns about reproducibility of results. Furthermore, these dressings are manufactured as pads that work well on planar surfaces but some investigators have reported difficulties in conforming them to deep, narrow wounds or wounds of more irregular shapes.
Human Fibrin Dressings
Originally reported by Gray in 1915, 20 the use of human fibrinbased products was discarded after World War II because of concerns about transmission of hepatitis. Since the mid-1990s there has been a renewed interest in hemostatic properties of human fibrin especially in dried formulations (for ease of storage and application). 21 This effort has been spearheaded by an alliance between the U.S. Army and the American Red Cross. The active components of the dried fibrin dressing are powdered fibrinogen, thrombin, factor XIII (all from human sources), and calcium. So far studies have shown effectiveness in controlling hemorrhage from a variety of sources such as renal injuries, 22 ballistic extremity injuries, 23 liver injuries, 24, 25 and aortic puncture. 26 This new generation of dried fibrin dressing has largely eliminated the risk of viral transmission, is stable at room temperature, and requires no mixing of components (needed for some other fibrin-based liquid agents). It is expensive, however (about $1,000 per dressing), slow to manufacture, and has not yet received FDA approval for clinical use. All of these factors limit its use in the battlefield. A limited supply of dressings (approximately 500) have been sent to the troops in Iraq under a Compassionate Use Investigational New Drug (IND) protocol, but no use has been reported to date.
Mineral Zeolite Hemostatic Agent
A manufactured granular mineral zeolite has recently been shown to have superb hemostatic properties. It is an inert mineral product composed of oxides of silicon, aluminum, sodium, and magnesium and small amounts of quartz. This synthetic zeolite acts as a molecular sieve and adsorbs water. This exothermic process is purely physical and not chemical in nature, and the extent of heat generated depends upon the ratio of zeolite to water. The adsorption of water concentrates the platelets and clotting factors and promotes rapid clot formation.
In a swine model of lethal vascular and soft tissue injuries of the groin, 3.5 oz of zeolite hemostatic agent (ZH) applied 5 minutes after injury (QuikClot; Z-Medica LLC, Newington, Connecticut) has been shown to significantly decrease mortality. 27 This animal model was created to mimic hemorrhage from sites that are not suitable for application of tourniquets or compressive dressings (e.g., complex groin wounds), as seen during the conflicts in Somalia and Afghanistan 8, 28 . In this experiment, transection of femoral artery, vein, and muscles at the level of inguinal ligament resulted in 83% mortality in the control (no dressing) group. Application of standard dressing, in conjunction with limited fluid resuscitation, decreased the mortality to 33.4%. Addition of ZH offered statistically significant advantage by decreasing the mortality rate to 0%. The use of ZH was also associated with the lowest volume of blood loss. Mortality rates for other hemostatic agents were: RDH (Marine Polymer Technologies) 66.6%, and TraumaDEX (Medafor, Inc., Minneapolis, Minnesota) 33.4% (Fig. 1) . Because of the exothermic reaction, there was a rapid (within 30-60 s) but brief (a few minutes, with peak temperatures lasting approximately 30 s) increase in wound temperature. The maximum temperatures ranged between 42 and 44°C.
Altering the residual moisture content of zeolites can decrease heat generation, but its effect on the hemostatic properties is unknown. In a follow-up study, ZH formulations with increased residual moisture content (1%, 4%, and 8%) were tested as well as a smaller dose (2 oz) of 1% moisture ZH. 29 The application of 1% ZH decreased blood loss and reduced mortality to 0% (p Ͻ 0.05) (Fig. 2 ). An increase in the residual moisture content adversely affected efficacy of the hemostat without any significant decrease in the maximum wound temperatures (50-60°C). An increase in the exothermic reaction was noted compared with the first study. This was most likely attributable to altered ratio of blood to ZH, because the dressing was applied earlier (3 minutes vs. 5 minutes), and the animals were resuscitated more aggressively. Minimal histological tissue damage was noted in all ZH groups, which was independent of residual moisture. The clinical relevance of the histological tissue damage is debatable because most of the severe combat wounds routinely undergo debridement. Furthermore, the use of ZH has been described in humans for life-threatening hemorrhage without any complications from the exothermic reaction. 30 Although the risks of exothermic reaction are clearly acceptable in the setting of a lifethreatening injury (as created in this model), the use of ZH may have an unacceptable risk:benefit ratio if used for minimal, nonlethal wounds. It must be stressed that to achieve optimal results with all the hemostatic agents described in this article, direct manual compression must be applied on top of the dressing until clot formation (approximately 5 minutes).
Zeolite hemostat with 1% residual moisture (QuikClot) received FDA approval for clinical use through a 510(k) submission in May 2002, and it has been included as a key component of the newly redesigned U.S. Marine Corps individual first aid kit (Fig. 3) . This agent is relatively inexpensive ($10 per packet), easy to manufacture, and extremely durable (more information available at www.z-medica.com). Following its initial successful use in Afghanistan (by special operations units), more than 50,000 units of the hemostat have been deployed to the U.S. troops (primarily the Marine Corps) in Iraq.
Recommendations for the Use of Zeolite Hemostat by the U.S. Marine Corps
This agent although extremely effective carries the potential risk of thermal injury. At least three other studies have demonstrated the effectiveness of zeolite hemostat, QuikClot (QC): in a swine model of skin, liver, spleen, and vascular injuries (J. Wright, unpublished data), liver injury in swine (A.E. Pusateri, unpublished data) and aortic puncture injury in rodents (C.R. Valeri, unpublished data). These investigators reported variable amounts of thermal damage to the tissues as a result of the heat generation. At the request of the Marine Corps, because these data are as yet unpublished, an expert panel was assembled at the Uniformed Services University, Bethesda, Maryland (February 21, 2003) to review all of the available data and make recommendations (and establish guidelines) for the use of this agent in the battlefield. The panel recommended the use of QC in situations where the standard therapy has failed and urged that it be supplied to the Marines as soon as possible. In their report, the panel concluded that QuikClot is an extremely effective hemostatic agent and the "potential for tissue damage is offset by the opportunity to save a life in otherwise uncontrolled external hemorrhage." To ensure proper usage, the indications for its use, methods of application, and training requirements were described in detail by this group of experts. Appendix I outlines the steps involved in the application of this agent to the bleeding site.
U.S. Army Policy Regarding the Use of QuikClot
Although the U.S. Marine Corps has included this hemostat in the individual first aid kits, the U.S. Army decided to limit the distribution of QuikClot to selected medical care providers. Similar to the U.S. Marine Corps approach, this hemostat will be used in situations where conventional treatment has failed. Salient points from the Army Medical Department policy (February 2003) are attached as Appendix II.
Summary and Discussion
Controlling hemorrhage will always remain a top priority in trauma care, and the development of materials to achieve this goal more effectively is of obvious benefit. The trend in modern warfare is toward rapidly moving nonlinear battlefronts and urban conflicts, 31, 32 with terrorist activities and guerrilla warfare replacing the traditional combat between well-organized armies. Because of the overwhelming superiority of the U.S. military, the conventional wars are likely to be brief, but the post war period may be characterized by prolonged conflicts in urban areas or in hostile terrain between an ill-defined enemy and small rapidly mobile U.S. combat units. This pattern is currently evident in Afghanistan as well as in Iraq. Compared with previous wars (such as Korea and Vietnam) where the evacuation was rapid and field hospitals were close to the front lines, conflicts in urban or hostile environment are characterized by unforeseen delays in evacuation 33 and delivery of definitive surgical therapy. Theoretically, early and effective hemorrhage control is even more important in these situations and can save more lives than any other measure; however, the best strategy to achieve this goal in austere and hostile combat situations remains controversial.
In response to the changing combat casualty care, there has been an increase in efforts to develop better hemostatic agents. An ideal agent should be effective, easy to use, safe, logistically superior, and durable. The use of effective hemostatic dressings will benefit most combat injuries (whether they are life threatening or not) because better hemorrhage control is always advantageous. The development of a hemostatic agent that is easy to apply by a layperson, including the injured combatant, is an exciting and relevant goal. Although a perfect hemostatic dressing has not yet been developed, this report describes some of the products that have been deployed to the warfront and others that may be available soon.
A closer look at the FDA-approved hemostats reveals a mixed picture. The RDH bandage has failed to demonstrate consistent efficacy, prompting the manufacturer to modify the dressing. This new configuration will require further testing before it can be deployed. The chitosan dressing (HemCon) is very promising but needs further testing. The difficulties with production (especially batch to batch variability) also need to be resolved. The QuikClot hemostatic agent is extremely effective, but there are risks involved with its use as a result of the exothermic reaction. Finally, these agents have not been tested in trauma patients, and there is a clear need for a well-designed clinical trial.
The current war effort required urgent deployment of hemostatic agents to the troops. In the absence of a definitive comparative study, the choices made relied upon the best available information, which may change over time. It should also be emphasized that such a policy decision is inherently more complex than a straightforward risk benefit analysis for an individual patient in any clinical situation. For the military, benefits of an individual life saved have to be balanced against the optimal choice for the largest number of personnel. The option that best serves these two goals is not always the same. The unique Mortality rates in different groups. ‫,ء‬ p Ͻ 0.05 using analysis of variance and Dunnett's test for multiple comparisons against the no-dressing group. ND, no dressing; SD, standard dressing alone; 1% ZH, SD ϩ 3.5 oz of zeolite hemostat with 1% residual moisture; 4% ZH, SD ϩ 3.5 oz of zeolite hemostat with 4% residual moisture; 1% ZH 2 oz, SD ϩ 2 oz of zeolite hemostat with 1% residual moisture; 8% ZH, SD ϩ 3.5 oz of zeolite hemostat with 8% residual moisture; HC, SD ϩ HemCon hemostatic dressing; NZH, SD ϩ 3.5 oz of nonzeolite hemostat (Quick Relief); FA, SD ϩ FastAct bovine hemostatic dressing; TDex, SD ϩ 30 g of TraumaDex hemostatic powder.
combat conditions, logistical constraints, and training issues further influence such decisions. In addition, it must be emphasized that none of these agents will stop hemorrhage unless used properly. Although the exact number may be higher, use of QC has been reported in approximately 50 cases so far. In the vast majority of the patients, its use resulted in an impressive control of hemorrhage that saved limbs and lives. In four case reports, however, it was used incorrectly (no compression) and failed to stop the bleeding. 34 Clearly hemostatic agents are not a substitute for, but an adjunct to, the standard treatment, and adequate training of the user will be a key factor in obtaining the desired benefit. It is too early to determine the direct impact of these new strategies on combat casualty outcomes; however, it is very encouraging to note that for the first time since the Crimean war, the KIA rate has markedly dropped below the historic 20%. In Iraq, the KIA rate was initially 20%, but a recent analysis of 470 U.S. military deaths (325 KIA, 145 non-hostile killed, 2,333 wounded in action, 370 non-hostile wounded) reveals an overall KIA rate of only 12.2%. 35 As with any new development, there is considerable debate to determine the "best" hemostatic agent for combat injuries. A number of meetings have been held to discuss this issue including: During these meetings (attended by authors of this article) there was a general agreement that an "ideal hemostatic dressing" is not yet available and further research should continue. Both of the dressings that have been deployed (HemCon and QuikClot) have shown effectiveness in preclinical studies but none is clearly superior. Because of the differences in their physical properties, handling characteristics, and logistical requirements they should be considered complementary; for example QuikClot may be more suitable for deep jagged wounds whereas HemCon might be a better choice for wounds on an even surface. The Committee on Tactical Combat Casualty Care (containing members from all military services, the Surgeon General of the United States, and civilian trauma experts) has recommended that both of these dressings should be deployed by all military services. According to the COTCCC recommendations, all the bleeding wounds should initially be treated with standard of care (pressure dressings, tourniquets, etc.). If the bleeding continues, application of HemCon with manual compression should be the next step. This decision was based on the fact that although HemCon is less effective than QuikClot it has no side effects. Finally, if the bleeding still does not stop then HemCon should be removed and QuikClot applied with manual compression for 5 minutes as a lifesaving measure. The recommendations of this committee will also be included in the next edition of the Prehospital Trauma Life Support manual that is produced by the National Association of Emergency Medical Technicians in cooperation with the Committee on Trauma of the American College of Surgeons.
This article reviews the dressings that have been deployed to the battlefield, emphasizing the unique features of each agent. A simple and easy to follow algorithm is also presented (Fig. 4) that emphasizes the two-tier approach to limit the use of hemostatic dressings to those who really need it and optimize the risk: benefit ratio. As illustrated, the initial attempt should be to use standard therapy (packing, circumferential dressing, or tourniquet depending upon the nature and location of the injury). If bleeding is controlled, the dressings should be left in place until evacuation to a higher level of care; however, if the bleeding continues after proper application of standard treatment, the responder should switch to hemostatic agents. The choice of the hemostatic agent should be dictated by availability, nature of the wound, and the training level of the user. In the absence of any limiting factors, the COTCCC recommendations as described above should be followed. Although the discussion in this article has focused on combat injuries, the rationale for the early use of hemostatic dressings applies equally well to the prehospital treatment of civilian trauma.
